Tragara Pharmaceuticals, Inc.: Clinical Trials

4 trials sponsored by Tragara Pharmaceuticals, Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4

Follow Tragara Pharmaceuticals, Inc.: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
TG02, Radiation Therapy, Temozolomide - Astrocytoma, Grade III, Glioblastoma
Phase 1CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC712018-06-122025-11-26
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
TG02 citrate - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1CompletedTragara Pharmaceuticals, Inc.162012-09-012019-07-25
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
TG02 citrate, Carfilzomib, Dexamethasone - AML, ALL
Phase 1CompletedTragara Pharmaceuticals, Inc.1202010-08-012016-05-06
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients
TG01 - Non-small Cell Lung Cancer
Phase 1CompletedTragara Pharmaceuticals, Inc.452007-10-012010-03-17

Conditions studied

Astrocytoma (1)  ·  Blast Crisis (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Glioblastoma (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Multiple Myeloma (1)

Interventions

14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (1)  ·  Calcium Dobesilate (1)  ·  Dexamethasone (1)  ·  Radiotherapy (1)  ·  Temozolomide (1)  ·  carfilzomib (1)

Countries

United States (3)  ·  Austria (1)  ·  France (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Switzerland (1)

Top investigators

T Parrott (2)  ·  Emilie Le Rhun (1)  ·  Sara Zaknoen, MD (1)

NIH funding

2017 (1)